Literature DB >> 11704384

To ablate or operate? that is the question!

E D Wigle, L Schwartz, A Woo, H Rakowski.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11704384     DOI： 10.1016/s0735-1097(01)01594-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  4 in total

1.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

2.  Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society.

Authors:  L Faber; H Seggewiss; F H Gietzen; H Kuhn; P Boekstegers; L Neuhaus; L Seipel; D Horstkotte
Journal:  Z Kardiol       Date:  2005-08

3.  Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.

Authors:  Christian Sohns; Samuel Sossalla; Jan D Schmitto; Claudius Jacobshagen; Björn W Raab; Silvia Obenauer; Lars S Maier
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

4.  Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.

Authors:  F H Gietzen; C J Leuner; L Obergassel; C Strunk-Mueller; H Kuhn
Journal:  Heart       Date:  2004-06       Impact factor: 5.994
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.